Riferimento farmaci
Ponatinib
Ponatinib is a medicine in the class oncology. It is used for acute lymphocytic leukemia.
- Classe del farmaco: Oncology
- Indicato per: acute lymphocytic leukemia
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01EA05
- Forme farmaceutiche comuni
- compressa
- Dosaggi comuni
- 15 mg
- Interazioni note
- 114 (Maggiore: 18 · Moderata: 60 · Minore: 36)
- Nomi commerciali
- 3
- Paesi e mercati
- 3
Per cosa si usa
Come agisce
Ponatinib is a kinase inhibitor that inhibits ABL and T315I mutant ABL tyrosine kinase activity in vitro, and also inhibits VEGFR, PDGFR, FGFR, EPH receptor and SRC family kinases, KIT, RET, TIE2 and FLT3.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Newly diagnosed Ph+ ALL: 30 mg orally once daily with chemotherapy; reduce to 15 mg once daily on MRD-negative CR at end of induction; continue up to 20 cycles until loss of response or unacceptable toxicity
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after.
- Allattamento
- Unsafe No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
Effetti indesiderati segnalati
- Rash and related conditions
- Arthralgia
- Abdominal pain
- Fatigue
- Headache
- Constipation
Avvertenze in evidenza
- Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors. Venous thromboembolic events, heart failure (including fatalities) and hepatotoxicity (liver failure and death) have occurred. Monitor, and interrupt or discontinue based on severity.
Chi deve prestare attenzione
- Hypertension: monitor blood pressure and manage; interrupt, reduce or stop if not controlled.
- Pancreatitis: monitor serum lipase.
- Myelosuppression: CBC every 2 weeks for first 3 months, then monthly or as indicated.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (114)
- Apalutamide + Ponatinib Major
- Carbamazepine + Ponatinib Major
- Chloramphenicol + Ponatinib Major
- Clarithromycin + Ponatinib Major
- Daunorubicin + Ponatinib Major
- Deferiprone + Ponatinib Major
- Edoxaban + Ponatinib Major
- Enzalutamide + Ponatinib Major
- Eslicarbazepine + Ponatinib Major
- Imatinib + Ponatinib Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Ponatinib: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Ponatinib used for?
Ponatinib is a medicine in the class oncology. It is used for Acute lymphocytic leukemia, Leukemia.
What side effects have been reported with Ponatinib?
Rash and related conditions, Arthralgia, Abdominal pain, Fatigue, Headache, Constipation. Serious warning: Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors.
Can Ponatinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after. Breastfeeding: Unsafe. No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
What does Ponatinib interact with?
MediHelp lists 114 known interactions for Ponatinib. Major: 18 · Moderate: 60 · Minor: 36. The most serious include Apalutamide, Carbamazepine, Chloramphenicol.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
